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Early diagnosis and effective treatment of cancer are essential 
to minimize morbidity and mortality. These goals can be 
achieved by combining 1) disease-specific molecules that may 
serve as both diagnostic markers and therapeutic targets with 
2) imaging and drug delivery tools capable of providing high-
performance intervention on diseased sites without (or only 
marginally) affecting nearby or distant healthy tissues. Despite 
this broadly accepted assumption, progress in patient-tailored 
approaches has been relatively slow, particularly due to the 
paucity of suitable molecular markers. For example, of the 
~1,500 proteins proposed as new cancer biomarkers in the 
decade 2000-2010, only < 20 have been approved by the Food 
and Drug Administration (FDA) to be used in routine testing [1]. 
On the other hand, applications of nanotechnology to medicine 
(collectively defined as nanomedicine) are experiencing a 
tremendous impact on next-generation cancer management, 
as demonstrated by the number of ongoing clinical trials 
and advanced preclinical studies [2, 3]. A nanomedicine is a 
therapeutic, diagnostic or combined (theranostic = therapeutic 
+ diagnostic) agent embedded in, or otherwise associated to, 
a nanoparticle to provide better biodistribution, improve the 
efficacy and/or reduce the toxicity of the agent itself. In our 
studies, we identified new biomarkers and explored preclinical 
applications of targeted nanomedicines for cancer imaging 
(targeted fluorescent nanoparticles) and treatment (targeted 
drug-loaded liposomes). In this minireview, we outline the 
principal findings of these studies.
Targeted molecular imaging of metastatic 
colorectal cancer
Our research group has described a previously unknown 
complex of α
6
 integrin and E-cadherin, which is present on 
the surface of colon cancer cells but not of normal colon cells 
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[4]. We have also identified a specific ligand to this receptor 
complex, namely angiopoietin-like 6, a factor secreted in high 
amounts by normal liver and physiologically involved in lipid 
metabolism. We have demonstrated that this receptor/ligand 
circuit is operative in secondary tumor spreading: colon cancer 
cells expose the receptor, normal liver cells secrete the 
ligand, and their mutual recognition allows cancer cells to 
colonize the liver and eventually produce a metastatic mass 
in this site [4].
In addition, we have characterized two angiopoietin-
like-6 mimicking peptides that bind the α
6
 integrin/E-cadherin 
complex. These peptides, of sequence CGIYRLRS and 
CGVYSLRS (single letter amino acid code), besides competing 
with angiopoietin-like 6 for binding the receptor complex (and 
therefore inhibiting hepatic metastasis), represent potential tools 
to flag tumor cells that expose both α
6
 integrin and E-cadherin 
[4]. So, we have exploited their binding properties to design 
nanomedicines for cancer imaging [5]. This study was based 
on silica nanoparticles, which exhibit favorable toxicological 
profile and biocompatibility in vivo coupled to ease of 
manipulation in vitro [6, 7]. We produced modular nanosystems 
to obtain an imaging platform consisting of fluorescent silica-
polyethylene glycol (PEG) nanoparticles (SPNs) that expose 
either the CGIYRLRS or CGVYSLRS peptide on their surface. 
These SPNs have a silica nucleus associated to one or more 
alkoxysilane-derivatized fluorescent dyes, included in a micelle 
of the copolymer Pluronic®F127. In other words, they consist of 
a PEG shell incorporating a dye-doped silica core. The external 
PEG provides a standard of stealth polymer for stable dispersion 
in physiological conditions and for prevention of uptake by the 
phagocyte system. Moreover, the PEG tails can be derivatized 
to allow covalent attachment of targeting peptides. Our 
SPNs have a core diameter of 11 ± 3 nm, a hydrodynamic 
diameter of 23 nm and are doped with either Rhodamine A 
(Rhod), Cyanine 5 (Cy5) (single-color), or both (dual-color). 
Their specificity was first investigated ex-vivo on patient-
derived specimens of hepatic metastasis, compared to normal 
liver and to primary colon cancer (Fig. 1). Sections of frozen 
human tissues were incubated with control (untargeted) and 
dual-color peptide-targeted (Rhod+Cy5)-SPNs. Nanoparticle 
selectivity was evaluated by confocal microscopy (imaging; 
Fig. 1A–D, quantification; Fig. 1E), revealing specific binding of 
CGIYRLRS- and CGVYSLRS-(Rhod+Cy5)-SPNs on hepatic 
metastasis (Fig. 1B) compared to normal liver (Fig. 1A) and 
colon (Fig. 1C), and to the primary tumor (Fig. 1D).
The SPNs were also tested in vivo in a mouse model of 
pseudo-metastatic tumor (human colon cancer cells implanted 
into the spleen of non-obese diabetic/severe combined 
immunodeficient mice, NOD/SCID; Fig. 2). Tumor-bearing mice 
were injected with control and targeted SPNs and signal was 
detected after increasing circulation times starting at 1 hour. At 
6 hours, we observed a substantial reduction in background 
fluorescence and this signal-to-background ratio remained 
consistent at 16 and 24 hours. This suggests that clearance of 
untargeted nanoparticles is accompanied by accumulation of 
targeted SPNs in metastatic foci, providing a large timeframe 
for applications to be translated to the clinics. Fluorescence 
imaging by stereomicroscopy and confocal microscopy 
confirmed a metastasis-specific accumulation of (Rhod)-
CGIYRLRS-SNPs (Fig. 2A, D, G, H), (Cy5)-CGIYRLRS-
SNPs (Fig. 2 B, E, I, J) and (Rhod-Cy5)-CGIYRLRS-SNPs 
(Fig. 2C, F, K, L, M, N). A tridimensional reconstruction of 
several confocal microphotographs showed that the targeted 
SNPs localize in close proximity of tumor blood vessels 
(Fig. 2O, P).
The intra-operative use of fluorescence tracers is starting 
to emerge in prostate, gastric, urinary and ovarian cancers 
[8–11]. Fluorescent imaging of externally accessible human 
cancers, namely nonmelanoma skin tumors can be achieved 
[12] and endoscopic fluorescence imaging systems have also 
been developed for applications in colon cancer [13]. All these 
systems are based on untargeted fluorescent tracers, while 
our SPNs have the additional feature of being molecularly 
targeted, providing further proof of feasibility for translational 
consideration.
 
Targeted drug delivery in metastatic neuroblastoma
In the past years, we and our collaborators have also identified 
peptides with unique targeting features for applications in 
tumor treatment. Among these, CPRECES [14] and CNGRC 
[15] (single letter amino acid code) bind with high selectivity to 
the tumor endothelial/perivascular markers aminopeptidase A 
(APA) and N (APN), respectively, so they are optimal for in vivo 
applications of drug delivery via the circulation.
These two peptides were exploited in a first study aimed to 
define the preclinical feasibility of targeted nanomedicines for 
doxorubicin (DXR) delivery to models of infantile neuroblastoma 
[16]. For this purpose, a synthetic version of each peptide was 
produced as fusion with human tumor necrosis factor (TNF) 
and the short linker KY (single letter amino acid code), and then 
coupled to the PEG tails of stealth liposomes (SL) composed 
of distearoyl phosphatidylethanolamine (DSPE)-PEG, 
hydrogenated soy phosphatidylcholine (HSPC) and cholesterol. 
These SLs were loaded with DXR to obtain the targeted 
Silica nanoparticle 
Liposome
Rhodamine B 
Doxorubicin (DXR) 
Cyanine 5 
Targeting peptide 
Targeting peptide 
Lipidic arm 
Lipidic arm 
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Fig. 1. Frozen sections of (A) normal liver, (B) hepatic metastasis, (C) normal colon and (D) primary tumor were fixed in 4% formaldehyde, before incubation with 
untargeted, CGIYRLRS-, or CGVYSLRS-(Rhod+Cy5)-SPNs for 4 hours at room temperature. After washing, SPN-emitted fluorescence was analyzed by confocal 
microscopy and the output was converted into the false-color LUT Fire scale for prompt visualization. Nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI). 
Colocalized pixels were identified by ImageJ software. Experiments were performed with similar results on specimens from 10 patients with metastatic CRC; exemplary 
images from tissues of patient #P85 are shown. (E) Quantification of SPN binding is expressed as the intensity of emitted pixel following excitation at 514 nm (Rhod) 
and 633 nm (Cy5), and represents a mean value of 5 images for each tissue. From Soster et al. [5]
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nanosystems CPRECES-SL[DXR] and CNGRC-SL[DXR], 
respectively, with a size of 90–115 nm, drug entrapment of 95% 
and peptide coupling of 4 µg/µmol of SL. For pharmacokinetic 
studies, these SLs were dual-labeled by incorporation of 3H 
and 14C in cholesterol and DXR, respectively, demonstrating 
suitable stability and long circulation times (up to 24 hours) [16]. 
The efficacy of such formulations, either as a single agent or in 
combination regimens (COMBO), was evaluated in orthotopic 
models derived by implant of human neuroblastoma cells into 
the left adrenal gland of nude mice. Starting 21 days after 
tumor cell implant, mice were treated once a week for 5 weeks 
with 5 mg/kg DXR (free or liposome-incapsulated), showing 
that administration of CPRECES-SL[DXR], CNGRC-SL[DXR] 
and COMBO provided a consistent lifespan extension vs. the 
free drug (up to 17, 37 and 66 days, respectively; Fig. 3) [16].
This work demonstrates that targeting a drug to the tumor 
microenvironment increases its efficacy and can therefore be 
exploited for the development of innovative medicines.
Based on these encouraging results, in a successive 
study we performed combined in vitro/ex-vivo screenings of 
Rhod
Cy5
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Fig. 2. NOD/SCID mice bearing a primary tumor and multiple liver metastases were injected with single- [control (A, Rhod; B, Cy5) or CGIYRLRS- (D, Rhod; E, 
Cy5)] or dual-color [control (C) or CGIYRLRS (F)] SPNs. After 16 hours, mice were euthanized and explanted organs were photographed with a high-resolution 
digital camera connected to a fluorescence stereomicroscope. In D, E, and F, orange arrows indicate blood vessels crossing the hepatic metastasis; in E and F, 
white arrows indicate sub-millimetric metastatic foci. Samples of the same tissues were OCT-frozen, cut into 10-µm slices, and evaluated by confocal analysis 
of single- [control (G, Rhod; I, Cy5), CGIYRLRS (H, Rhod; J, Cy5)] or dual-color [control (K), CGIYRLRS (L)] fluorescence. To visualize blood vessels, staining for 
CD31 was superimposed to the SPNs signal and visualized by the secondary antibodies Alexa Fluor®647 (G–H), Alexa Fluor®488 (I–J) and DyLightTM405 (K–N), 
for overlay with (Rhod)-SPNs, (Cy5)-SPNs and dual-color SPNs, respectively. In the case of dual-color SPNs, samples of primary tumors from mice injected with 
either control (M) or CGIYRLRS (N) SPNs are visualized as a further negative control. In O (detail of the field in J) and P (detail of the field in L), tridimensional 
models of 50–80 confocal image series were reconstructed with IMARIS software. From Soster et al. [5]
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phage-displayed peptide libraries to identify novel peptide 
motifs with high specificity for human neuroblastoma [16]. 
These experiments were designed to isolate peptides capable 
of binding the whole primary tumor (n = 26 motifs retrieved) 
or metastatic mass (n = 15 motifs), the primary tumor 
microenvironment (ME) (n = 57 motifs) or the metastasis ME (n = 
23 motifs). The specificity of 5 peptides targeting the metastatic 
mass (phage clone #14, peptide sequence KSFFLSH), the 
primary tumor ME (#1, YEGLISR) and the metastasis ME (#5, 
HSYWLRS; #8, WSWPREL; #10, ALAAHKL) was confirmed 
ex vivo by binding assays on sections of human stage IV 
neuroblastoma and in vivo in mouse models. These peptides 
were therefore synthetized with the addition of an N-terminal 
(YSHS, single letter amino acid code) and a C-terminal 
(GGG, single letter amino acid code) linkers and coupled to 
SLs as described above [16]. The potential efficacy of these 
nanosystems was tested in an orthotopic model derived from 
implant of luciferase-transduced human neuroblastoma cells; in 
addition, a pseudo-metastatic model was obtained by tumor cell 
injection in the tail vein of nude mice. Orthotopically-implanted 
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Fig. 3. Therapeutic efficacy of APN- and APA-targeted liposomal formulations in mouse models of neuroblastoma. Nude mice (8/group) implanted orthotopically with 
human neuroblastoma cells were treated (starting 21 days after tumor implant) by intravenous administration of HEPES-buffered saline (control), CNGRC-SL[empty], 
CPRECES-SL[empty] or 5 mg/kg of DXR, either free (DXR) or encapsulated in untargeted (SL[DXR]), APN- (CNGRC-SL[DXR]) or APA-targeted (CNGRC-SL[DXR]) 
liposomes or an equimolar mixture of CNGRC-SL[DXR] and CNGRC-SL[DXR] (COMBO), once-a-week for a total of 5 weeks. The efficacy of each formulation was 
evaluated in terms of survival and is expressed in a Kaplan–Maier graph as % of alive mice at different timepoints. From Loi et al. [18]
Fig. 4. (A) Therapeutic efficacy of peptide-targeted liposomal formulations in mouse models obtained by orthotopic implant of luciferase-expressing human 
neuroblastoma cells. Treatments started 21 days after tumor implant. Mice (5/group) were administered intravenous with HEPES-buffered saline (control), or 5 mg/kg 
of DXR, either free (DXR) or encapsulated in untargeted (SL[DXR]), scramble peptide- (SCR-SL[DXR] or targeting peptide-functionalized (1-, 5-, 8-, 10-, 14-SL[DRX]) 
liposomes, once-a-week for a total of 3 weeks. Tumor growth was monitored by BLI 5 days after each treatment (days 26, 33, 40 from tumor implant). Values are 
reported as fold increase in tumor volume compared to pre-treatment (day 20). Exemplary pictures of X-ray acquisitions one month after the end of treatment (day 65), 
relative to mice treated with SL[DXR], 5-SL[DXR] or 10-SL[DXR], are shown. (B–C) Therapeutic effect of the targeted formulations evaluated in terms of overall survival 
in both the pseudo-metastatic model (13 animals/ group, B) and the orthotopic model (8 animals/group, C). Statistical analysis: A, p vs. SL[DXR]; B–C, p vs. control, 
SL[DXR] and SCR-SL[DXR]. From Loi et al. [16].
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mice were treated once a week for 3 weeks starting 21 days 
after tumor cell implant, and intravenously-implanted mice 
were treated with the same schedule but starting 4 hours after 
tumor cell implant. In a first series of experiments, growth 
of luciferase-expressing orthotopic tumors was monitored 
by bioluminescence imaging (BLI) at days 26, 33, 40 after 
implant (5 days after each treatment) showing that 5-SL[DXR] 
and 10-SL[DXR] were the most efficient in delaying tumor 
progression, as also confirmed by a whole-body X-ray scan 
performed one month after the end of treatments (Fig. 4A). 
Successively, the capacity of targeted formulations to prolong 
the lifespan of tumor-bearing mice was evaluated in both 
the pseudo-metastatic (Fig. 4B) and the orthotopic (Fig. 4C)
model. Again, treatment with 5-SL[DXR] or 10-SL[DXR] 
provided a survival advantage to neuroblastoma-bearing mice 
when compared to control animals or even to animals treated 
with DXR, either free or included in untargeted liposomal 
formulations [16].
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These preliminary findings were complemented by a 
successive in-depth characterization of the HSYWLRS peptide 
(#5 of the previous study) as a targeting moiety in preclinical 
applications [17]. Binding and internalization specificity was 
confirmed on additional cell lines and tissue specimens from 
animal models and human stage IV neuroblastoma. DXR-loaded, 
peptide-targeted SLs (HSWYLRS-SL[DXR]) were therefore 
produced and tested as in vivo drug delivery nanosystems. 
Vascular permeability was evaluated by administration of Evans 
Blue in neuroblastoma-bearing mice treated with HSYWLRS-
SL[DXR], observing a specific increase in dye extravasation and 
accumulation in orthotopic tumors, but not in non-tumor tissues 
(Fig. 5A). Treatment with HSYWLRS-SL[DXR] also increased 
perfusion of tumor blood vessels, as determined by intravenous 
injection of fluorescein isothiocyanate (FITC)-lectin and analysis 
of emitted fluorescence by confocal microscopy (Fig. 5B). 
These phenomena were accompanied by (1) enhanced tumor 
Fig. 5. (A) In vivo systemic permeability. Mice (3/group) bearing orthotopic tumors were treated, 28 days after, with a single bolus of DXR (5 mg/kg), encapsulated 
into untargeted (SL[DXR]) or HSYWLRS-targeted (HSYWLRS-SL[DXR]) liposomes, in combination with 1 mg of Evans Blue dye. Control mice (CTR) received HEPES-
buffered saline only. One hour after, mice were perfused, tumors and livers collected and Evans Blue extracted and quantified (O.D. 600 nm). Results are expressed 
as Evans Blue dye per g of tissue. **, p < 0.01: HSYWLRS-SL[DXR] vs. CTR and SL[DXR]. (B) Exemplary tumor sections from control mice or from mice treated with 
SL[DXR] or HSYWLRS-SL[DXR] and inoculated with FITC-lectin (green). Red: CD31. Blue: cell nuclei (DAPI). Scale bar: 40 µm. Graph on the right, numbers of FITC-
lectin positive cells. ***, p < 0.001, HSYWLRS-SL[DXR] vs. CTR and SL[DXR]. (C) Potentiated therapeutic efficacy of HSYWLRS-SL[DXR]. Mice (8/group) bearing 
orthotopic tumors were treated intravenous with 5 mg/kg of DXR, either free (free DXR) or encapsulated into SL[DXR] or HSYWLRS-SL[DXR] liposomes, once-a-week 
for 3 weeks (arrows). Control mice received HEPES buffer only (CTR). Survival: p < 0.0008: HSYWLRS-SL[DXR] vs. SL[DXR]). Insert: mean body weight at different 
timepoints. From Cossu et al. [17]
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accumulation of HSYWLRS-SL[DXR], but not of DRX included 
into an untargeted liposomal formulation, and (2) prolonged 
animal survival (Fig. 5C) in the absence of toxicity signs such 
as weight loss (Fig. 5C, inset). Additionally, the therapeutic 
efficacy of HSYWLRS-SL[DXR] was compared to that of 
free DXR by monitoring the in vivo growth of orthotopically-
implanted, luciferase-expressing human neuroblastoma cells 
with BLI, revealing that only the targeted liposomal formulation 
elicits effective antitumor responses (Fig. 6A–B) and prolongs 
the lifespan of tumor-bearing mice (Fig. 6C). The effect was 
also validated by positron emission tomography (PET) coupled 
with glucose consumption measurement. This analysis 
revealed that treatment with HSYWLRS-SL[DXR] led to a 
substantial inhibition not only of primary tumor growth but also 
of secondary tumor spreading (Fig. 7A), which was confirmed 
by animal autopsy in terms of both metastatic foci number 
(Fig. 7C) and overall metastasis volume (Fig. 7C).
FITC-lectin
BULLETIN OF RSMU   6, 2018   VESTNIKRGMU.RU| |
REVIEW    NANOMEDICINE
11
Fig. 6. (A) Lateral (tumor side) images from mice orthotopically implanted with luciferase-expressing human neuroblastoma cells. Animals were treated intravenously, 
once a week for 2 weeks (arrows), with 5 mg/kg of DXR, either free (free DXR) or encapsulated into HSYWLRS-targeted liposomes (HSYWLRS-SL[DXR]). CTR mice 
received HEPES-buffered saline. Tumor growth was monitored by BLI at day 20 (before treatment) and 40 (end of treatments) after tumor challenge. (B) Antitumor 
effects at the end of treatments; values are reported as fold increase in tumor volume at day 40 over day 20. *, p < 0.05: free DXR vs. CTR; **, p < 0.01: HSYWLRS-
SL[DXR] vs. free DXR; ***, p < 0.001: HSYWLRS-SL[DXR] vs. CTR; (C) HSYWLRS-SL[DXR] show potentiated therapeutic efficacy. Survival: p < 0.0025: HSYWLRS-
SL[DXR] vs. CTR and free DXR. From Cossu et al. [17]
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Fig. 7. Treatment with HSYWLRS-SL[DXR] inhibits secondary tumor spreading. Mice (4/CTR, 5/treatments) orthotopically implanted with luciferase-expressing human 
neuroblastoma cells were treated as reported in the legend of Figure 6 and tumor extension was evaluated by PET after 41 days (A). Glucose consumption maps (white 
arrows: primary tumor; black arrows: metastases). (B) Number and (C) volume of metastases following treatments. *, p < 0.05: free DXR vs. CTR; **, p < 0.01: HSYWLRS-
SL[DXR] vs. free DXR; ***, p < 0.001: HSYWLRS-SL [DXR] vs. CTR
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Together, these data support the development of the 
neuroblastoma-targeting peptide HSYWLRS as a powerful tool 
for therapeutic applications.
CONCLUSIONS
Early tumor diagnosis and efficient treatment (namely, a 
treatment that reaches max antitumor efficacy while sparing 
normal tissues) remain an open medical need. The advent of 
nanomedicine is delivering new tools that could revolutionize 
our approach to cancer monitoring and therapy, provided 
that we identify biomarkers with suitable properties. In 
fact, while the development of nanomaterials is rapidly 
expanding, we still need more selective targets to allow patient-
tailored approaches. In this perspective, our recent work 
contributed a number of targets and targeting moieties that 
were validated preclinically and could be exploited to develop 
clinical tools. 
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